TX-GALDERMA
Galderma, the leading company solely dedicated to advancing the future of dermatology, announced it will be attending the 2022 American Academy of Dermatology Annual Meeting to showcase its latest approved and investigational product updates. This includes clinical data presentations at its product theaters, advisory boards, and booth activities onsite as AAD returns in-person once more.
“We are excited to attend AAD to connect with the dermatology community and showcase our latest innovation and data across our complete dermatology portfolio,” said Baldo Scassellati Sforzolini, Global Head of Research & Development at Galderma. “Our presence underscores our commitment to developing and bringing to market dermatological solutions to address every skin need.”
A considerable amount of new data will be presented during the AAD Congress in the form of abstracts and oral presentations for nemolizumab, a first-in-class investigational monoclonal antibody directed against the interleukin-31 (IL-31) receptor, under clinical development for the treatment of atopic dermatitis and prurigo nodularis.
The data for prurigo nodularis include efficacy data of nemolizumab and its impact on itch and sleep disturbance. An additional seven abstracts look at a variety of aspects of the disease including its prevalence, current treatment practices and the effect of the disease on sleep, mental health disorders and gastrointestinal and hepatobiliary diseases. Three abstracts in atopic dermatitis look at the safety and efficacy of nemolizumab in adolescents and the impact of nemolizumab according to EASI and Scorad components.
Galderma will present thirteen study abstracts regarding its investigational monoclonal antibody that targets the IL-31 receptor, nemolizumab. Data comes from Phase 2 studies and real-world evidence. More details on Galderma’s activities can be found below.
Abstract # and Title |
First Author |
Presentation Date/Time (ET) |
Abstract #35226: Characterization of Pain in Prurigo Nodularis: An Online Survey-Based Study |
Prachi Aggarwal, BA |
Friday, March 25, 8:35 – 8:40 AM |
Abstract #35303: Treatment Practices and the Use of Web-based Resources in Prurigo Nodularis |
Prachi Aggarwal, BA |
Friday, March 25, 8:40 – 8:45 AM |
Abstract #35351: Association between prurigo nodularis and gastrointestinal and hepatobiliary diseases in adults: A national cross-sectional study. |
Adawi Waleed |
Friday, March 25, 8:55 – 9:00 AM |
Abstract #35165: Efficacy, Tolerability, and Cosmetic Acceptability of an Acne Regimen Specifically Designed for Sensitive Skin |
James Q. Del Rosso, DO |
Friday, March 25 8:55 – 9:00 AM |
Abstract #32846: DUAL Study: Trifarotene Plus Doxycycline Has Proven Efficacy and Safety in Severe Acne Vulgaris |
James Q. Del Rosso, DO |
Friday, March 25 9:00 – 9:05 AM |
Abstract #33284: Efficacy of nemolizumab in atopic dermatitis: Rapid impact on EASI and SCORAD components |
Jean-David Bouaziz, MD, PhD
|
Friday, March 25 11:15 – 11:20 AM |
Abstract #33317: Study of nemolizumab pharmacokinetics, safety, and efficacy in adolescents with atopic dermatitis |
Robert Sidbury, MD, MPH
|
Friday, March 25 11:20 – 11:25 AM |
Abstract #34945: An In-vitro Evaluation of a Niacinamide-Panthenol-Glycerin Complex on Skin Barrier Function, Hydration, and Neuro-Inflammation |
Dillon Nussbaum, BSc |
Friday, March 25 11:55 – 12:00 PM |
Abstract #34679: Association of adult atopic dermatitis severity with decreased physical activity: A cross-sectional study |
Gabrielle Schwartzman |
Friday, March 25 2:20 – 2:25 PM |
Abstract #35218: Sleep disturbance in adults with prurigo nodularis is associated with increased circulating C-reactive protein levels and adverse cardiovascular outcomes |
Varsha Parthasarathy |
Friday, March 25, 2:25 – 2:30 PM |
Abstract #33202: Prurigo nodularis and mental health disorders among hospitalized patients in the United States |
Thomas K Le |
Saturday, March 26, 1:25 – 1:30 PM |
Abstract #34095: Observed and Projected Prevalence of Prurigo Nodularis in a Commercially and Medicare-insured U.S. Population |
Shawn G. Kwatra |
Saturday, March 26, 2:40 – 2:45 PM |
Abstract #33307: Nemolizumab is associated with a rapid reduction of itch and sleep disturbance in patients with prurigo nodularis |
Sonja Ständer, MD
|
E-Poster |
Additionally, Galderma will be hosting four product theaters to discuss new research findings across our portfolio:
Product |
Topic |
Date/Time (ET) |
Location |
Acne: TWYNEO Cream & AKLIEF Cream |
Groundbreaking Acne Treatment: TWYNEO Cream: Dermatology’s Only Combination .1% Tretinoin and 3% BPO for Moderate to Severe Acne Vulgaris |
Friday, March 25 10:30 – 11:15 AM |
Theater 2 |
CETAPHIL Sensitive Skin |
Advancing Sensitive Skin: Diagnosis, Morphological Traits and Epidemiology |
Friday, March 25 12:00 – 12:45 PM |
Theater 1 |
CETAPHIL Pediatric |
Paediatric Atopic Dermatitis: Current Developments |
Saturday, March 26 12:00 – 12:45 PM |
Theater 2 |
IL-31 |
A Neuroimmune Perspective on Itch and Skin Inflammation in Atopic Dermatitis and Prurigo Nodularis – Introducing IL-31 |
Sunday, March 27 10:30 – 11:15 AM |
Theater 2 |
A series of Speakers Forum talks will be held on the Galderma booth #1117.
Topic |
Speaker |
Date/Time (ET) |
Location |
IL-31: A Neuroimmune Perspective of Atopic Dermatitis |
Jonathan Silverberg, MD, PhD, MPH |
Friday, March 25 12:10 – 12:25 PM |
Galderma booth #1117 |
Activate Skin Power with PLLA |
Susan H. Weinkle, MD |
Friday, March 25 12:30 – 12:55 PM |
Galderma booth #1117 |
Galderma Innovation |
JP York, PhD, Galderma Medical Affairs |
Saturday, March 26 12:10 – 12:25 PM |
Galderma booth #1117 |
Groundbreaking Acne Treatment: TWYNEO Cream: Dermatology’s Only Combination .1% Tretinoin and 3% BPO for Moderate to Severe Acne Vulgaris |
Omar Noor, MD, FAAD |
Saturday, March 26 12:30 – 12:55 PM |
Galderma booth #1117 |
The Rheology of Restylane Collection of Hyaluronic Acid Fillers |
Deirdre Hooper, MD |
Sunday, March 27 12:10 – 12:55 PM |
Galderma booth #1117 |
For more information on IL-31 and its role in the pathophysiology of atopic dermatitis and prurigo nodularis, visit www.IL31role.com .
About atopic dermatitis
Atopic dermatitis (AD) is a chronic, debilitating inflammatory skin disease, characterized by diffuse skin lesions and constant, severe disruptive itch.[1],[2]
Reported prevalence of AD varies greatly, ranging from 1% to 25% of the population depending on the geography and age range.[3]
AD can have a profound impact on patients’ quality of life, leading to sleep difficulties, psychological complications and causing secondary skin infections (bacterial and viral).[4]
About prurigo nodularis
Prurigo nodularis (PN) is a rare, potentially debilitating, chronic skin condition with thick skin nodules covering large body areas and associated intense unrelenting itch.[5]
While PN can occur at any age, it is most likely to affect people between the ages of 40 and 69, frequently leading to severe impairment in quality of life.[6]
The global prevalence of PN is not well known as there are few studies describing the epidemiology of the condition. In the U.S., the latest estimate is that PN affects 52.9 people in every 100,000.[4] In the European context, rates of between 0.65 and 11.1 per 10,000 population have been reported. In addition to natural variation, this relatively wide range of estimates is partly due to differences in case definition and the representativeness of the study populations.[6]
About nemolizumab
Nemolizumab is an investigational agent under clinical development for the treatment of atopic dermatitis and prurigo nodularis and its safety and efficacy have not been fully evaluated by any regulatory authority.
About Galderma
Galderma is the world’s largest independent dermatology company, present in approximately 100 countries. Since our inception in 1981, we have been driven by a complete dedication to dermatology. We deliver an innovative, science-based portfolio of sophisticated brands and services across Aesthetics, Consumer Care and Prescription Medicine. Focused on the needs of consumers and patients, we work in partnership with healthcare professionals to ensure superior outcomes. Because we understand that the skin we’re in shapes our life stories, we are advancing dermatology for every skin story. For more information: www.galderma.com/us
.
References
- Langan S. et al. Atopic dermatitis. The Lancet . 2020;396(10247):345-360. DOI: https://doi.org/10.1016/S0140-6736(20)31286-1
- Weidinger S. et al. Atopic dermatis. Nature Reviews. 2018. DOI: 10.1038/s41572-018-0001-z
- Silverberg, J, I. Public Health Burden and Epidemiology of Atopic Dermatitis.283-289. 2017.
- Galderma. Data on File. To be presented at AAD 2022.
- Galderma. Data on File. Press Release. Galderma presents new nemolizumab data at EADV. 2021.
- Morgan LI. Christopher. Epidemiology of prurigo nodularis in England. Accepted for publication in British Journal of Dermatology
- Saleem M. et al. Interleukin-31 pathway and its role in atopic dermatitis: a systematic review. J Dermatolog Treat. 2017;28(7):591-599. DOI: 10.1080/09546634.2017.1290205
View source version on businesswire.com: https://www.businesswire.com/news/home/20220325005215/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Launches 7th Edition of Good Food Makers to Shape the Future of Food2.7.2025 14:20:00 CEST | Press release
Barilla officially opens applications for Good Food Makers 2025, its open innovation program dedicated to startups and innovative companies focused on creating a more sustainable and connected food system. Now in its seventh edition, the program welcomes a new format — Good Food Makers – ECOSYSTEM — developed in collaboration with Almacube, the innovation hub of the University of Bologna and Confindustria Emilia. This year’s goal is to build a true innovation ecosystem by involving Barilla’s value chain partners and accelerating the adoption of emerging technologies. Three selected startups will join a four-week co-development journey with Barilla professionals and partner companies, working side-by-side to create impactful solutions across the entire food chain — from field to fork. Applications are open until the end of July, with the program running from September to January 2026, concluding with the Innovation Day. “Good Food Makers reflects our commitment to open innovation that g
SE Labs Award Reinforces NetApp Status as the Most Secure Storage on the Planet2.7.2025 14:00:00 CEST | Press release
NetApp wins 2025 SE Labs Award for Enterprise Data Protection NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced that it was recognized as a standout performer in cybersecurity in the SE LABS ® Awards 2025. NetApp won the 2025 SE Labs Award for Enterprise Data Protection, validating NetApp’s status as the most secure storage on the planet. This recognition as a winner of a 2025 SE Labs Award is a result of NetApp’s exceptional innovation in cyber resiliency to deliver NetApp ONTAP® Autonomous Ransomware Protection with Artificial Intelligence (ARP/AI), which was tested and validated by SE Labs. NetApp ARP/AI demonstrated 99 percent detection of tested, advanced full-file encryption ransomware attacks with zero false positives, indicating a strong ability to operate in a business context without contributing to alert fatigue. “Great security doesn’t just happen—it’s built, tested and proven,” says Simon Edwards, Founder and CEO of SE Labs. “Behind every
CroíValve Announces Funding from Horizon Europe EIC Accelerator2.7.2025 14:00:00 CEST | Press release
CroíValve, a pioneering medical device company innovating a better way to help more patients suffering from Tricuspid Regurgitation (TR), was awarded funding from Horizon Europe’s European Innovation Council (EIC) Accelerator Programme. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250702306192/en/ DUO™ Transcatheter Tricuspid System Part of the EU’s Horizon Europe 2021-2027 Research and Innovation Programme, the EIC Accelerator Programme provides transformational funding to high-potential, high-risk start-ups, scale-ups and subject matter experts. This award includes grant funding of €2.5 million, combined with an equity investment of €10 million in CroiValve’s next financing. The latest competition included 959 applications, with only 40 awards across 16 countries. Almost one third of the selected companies are led by a woman and CroiValve are incredibly proud to be one of this group. “Securing European Innovation Council
EUMETSAT: Europe’s First Geostationary Sounder Satellite Is Launched2.7.2025 13:20:00 CEST | Press release
Europe has taken a major step forward in strengthening its resilience to extreme weather events with the successful launch of the Meteosat Third Generation Sounder 1 (MTG-S1) satellite. MTG-S1 will deliver new streams of atmospheric data, enabling earlier, more accurate warnings that protect lives, property and infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250702002782/en/ MTG-S1 is part of the Meteosat Third Generation programme, Europe’s new fleet of geostationary meteorological satellites. Image: EUMETSAT Extreme weather events like storms, flooding, and heatwaves have caused hundreds of billions of euros in damage and claimed tens of thousands of lives across Europe in the past decades. Launched on 1 July 2025, MTG-S1 will provide Europe’s national meteorological services with high-frequency data on temperature, humidity and trace gases throughout the atmosphere – enabling forecasters to detect the earli
HCLTech and Equinor Expand Digital Collaboration2.7.2025 13:08:00 CEST | Press release
HCLTech, a global technology leader, and Equinor, Europe's largest energy supplier and a pioneer in renewables and low-carbon solutions, have expanded their IT collaboration to support the next phase of Equinor’s digital transformation. This expanded relationship will cover Equinor’s IT landscape across several key strategic areas. HCLTech will support Equinor as it accelerates its digital transformation by: Accelerating its cloud migration and standardizing services across operations Enhancing its cyber resilience and network performance Improving workplace experience through automation Enabling advanced user experiences with technologies like augmented reality (AR) "We’re pleased to continue our long-standing collaboration with Equinor," said Sandeep Kumar Saxena, Executive Vice President, HCLTech. "This collaboration reflects our shared commitment to innovation and sustainability.” Over the past decade, HCLTech has been a trusted advisor to Equinor, supporting the company’s global e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom